ARGX ArGEN-X SE

argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships

argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
EN
06/10/2020

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
BFIT BASIC-FIT NV
PNL POSTNL NV ... (+8)

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

BFIT BASIC-FIT NV
PNL POSTNL NV
QFG QUEST FOR GROWTH
ARGX ARGEN-X SE
UMI UMICORE
JDEP JDE PEET'S NV
BTLS BIOTALYS NV
ONWD ONWARD MEDICAL NV
8h / 43m 8h / 43m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FDA FAERS reporting flags Vyvgart Hytrulo in routine update

Yesterday during trading hours, the FDA flagged worsening of CIDP with Vyvgart Hytrulo as a new safety signal via a routine update to the FDA adverse event reporting system (FAERS), which sent the argenx' stock down approx. 8%. While CIDP worsening was also reported in patients switching between treatments from IVig to SCig in the PATH study, physicians navigate treatment switches carefully, and based on argenx' own post-marketing surveillance,

8h / 55m 8h / 55m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FIRST LOOK: ARGX-119 Ph1b shows POC in CMS, Ph3 in preparation

argenx announced its plan to advance the clinical development of ARGX-119 (muscle-specific kinase [MuSK] agonist antibody) to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the phase 1b study, which showed consistent improvements through the 12-week study across multiple efficacy scores. This marks the 3rd candidate to advance to phase 3 from argenx' internal pipeline, which in our view supports the company's future growt...

06/30/25 June 30, 2025 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Thomas Couvreur
LEAS LEASINVEST REAL ESTATE SCA
RET RETAIL ESTATES NV
AGFB AGFA-GEVAERT NV
ARGX ARGEN-X SE
FUR FUGRO NV
06/30/25 June 30, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthe...

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of p...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch